Radiopharm Theranostics Ltd has released a press release.
Radiopharm Theranostics: Half Year Report and Appendix 4D 31 December 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Radiopharm Theranostics
- RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics